Variations in the CYP2C19 gene lead to inappropriate concentrations of drugs or drug metabolites in the body, which may lead to toxicity, risk of adverse drug reactions or impaired drug efficacy. The PGX-CYP2C19 StripAssay^® detects genetic variants resulting in reduced or increased activity of the cytochrome P450 isoenzyme CYP2C19.

PGX-CYP2C19

• Patients carrying CYP2C19 variants may have an altered enzyme function and need dosage adjustment of drugs that are metabolized by this enzyme.
• CYP2C19 poor metabolizers have a diminished effectiveness of e.g. clopidogrel compared to CYP2C19 normal metabolizers and alternative platelet P2Y12 inhibitors should be considered. The poor CYP2C19 metabolism of certain drugs leads to a high plasma level of the drugs and in consequence to adverse events.
• CYP2C19 rapid metabolizers are likely to have failures in drug therapies due to a lack of response. These patients require an increased dose to achieve target levels of the drug.
• CYP2C19 loss-of-function alleles: *2 - *8, CYP2C19 gain-of-funcion allele: *17.
• Clinical guidelines providing drug prescribing recommendations are listed at PharmGKB: www.pharmgkb.org.
• The PGX-CYP2C19 StripAssay^® allows the discrimination between poor and rapid CYP2C19 metabolizer and in consequence helps to avoid adverse events or failure of therapy.